1 / 44

Board Review: Neurology

Board Review: Neurology. Matthew Volk 6/11/2010. Question #1. Guillain-Barre Syndrome. Immune-mediated, demyelinating polyneuropathy Proximal and distal weakness – including respiratory failure; Distal sensory loss Autonomic and cranial nerve involvement

Download Presentation

Board Review: Neurology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Board Review: Neurology Matthew Volk 6/11/2010

  2. Question #1

  3. Guillain-Barre Syndrome • Immune-mediated, demyelinating polyneuropathy • Proximal and distal weakness – including respiratory failure; Distal sensory loss • Autonomic and cranial nerve involvement • Most cases triggered by infxn, surgery, or immunization • CMV, EBV, HIV, Hepatitis, Lyme, campylobacter jejuni

  4. Guillain-Barre Syndrome • Treatment • Supportive care • Follow FVC and NIFs • Mechanical ventilation as needed • IVIg – avoid in CKD, CHF, IgA deficiency • Plasmapheresis – avoid in infxn, low BP • No benefit to combination therapy • Steroids not shown to help

  5. A few kinds of weakness Guillaume-Barre (AIDP) Myasthenia Gravis NMJ dysfunction Chronic and progressive Worsens with exertion, late in the day Oculomotor first Normal reflexes Sensory not involved • Demyelination • Acute after viral infxn • Worsens over 2-4 weeks then plateaus, resolves • Proximal limbs first • Absent reflexes • Can include sensory

  6. A few kinds of weakness • ALS – chronic progressive, ocular muscle sparing, hyperreflexia and spasticity (UMN disease) • Lambert Eaton – chronic but can resolve if malignancy-related, improves with exercise

  7. What does this patient have? • HPI: 54 y/o F with worsening SOB and inability to swallow x 2 days. Has had fatigue, difficulty keeping eyelids open, intermittent double vision x 1 month. • PE: shows bilateral ptosis, mild proximal weakness, normal reflexes.

  8. Question #2

  9. Question #2

  10. Acute Ischemic Stroke • Inclusion criteria for tPA • Age >18 years • Clinical diagnosis of ischemic stroke • Onset of symptoms within 3 hours of rx • CT without evidence of ICH • Key exclusion criteria • Rapidly improving symptoms • Persistent BP > 185/110

  11. Acute Ischemic Stroke • Aspirin to reduce rate of recurrent stroke; effect within 2 weeks • Subcutaneous heparin to prevent DVT • Airway protection/dysphagia screening • Blood pressure control in certain cases • Maintainence of normothermia • Hypothermia not studied in acute stroke • Aim for normoglycemia

  12. Acute Ischemic Stroke More on Blood Pressure control: • Hypertension protective unless extreme • Many would not treat unless >220 systolic • EXCEPT treat to goal 140-150 with MI, aortic dissection, hemorrhagic conversion • Recommended agents • Nicardipine, labetalol, nitroprusside

  13. Question #3

  14. Parkinsonism • Drug-induced Parkinsonism • Antiemetics, Antipsychotics, CCBs • Reversible with removal of offending agent • Neurodegenerative processes • Progressive Supranuclear Palsy • Multiple System Atrophy • Corticobasal Degeneration • Huntington’s Disease

  15. Parkinsonism • Essential Tremor • Restless Leg Syndrome • Focal/generalized dystonias • Cervical dystonia • Blepharospasm • Oromandibular dystonia • Spasmotic dysphonia • Ideopathic Parkinson’s Disease

  16. Parkinson’s Disease • Symptoms: resting tremor, rigidity, bradykinesia, postural instability • Treatments • Levodopa/carbidopa – older patients • Dopamine agonists – young patients • Amantadine – mainly works with tremor • Anticholinergics – young patients • MAO inhibitors – adjunctive therapy

  17. Normal Pressure Hydrocephalus • Gait Impairment • Cognitive Decline • Urinary Incontinence

  18. Some Dementias • Frontotemporal Dementia • Impaired executive function • Preserved visual-spatial function • Lewy Body Dementia • Visual hallucinations • Fluctuating cognition • Parkinsonism

  19. Question #4

  20. Multiple Sclerosis • Signs and Symptoms – develop over hours to days to years • Diplopia or Optic Neuritis • Hemiparesis • Hemisensory disturbance • Band-like sensations around trunk • Urinary retention • Cognitive decline

  21. Multiple Sclerosis • Treatment • Solumedrol followed by prednisone taper in acute exacerbations • Disease-modifying therapy – for relapsing-remitting disease • Interferon beta (Betaseron, Avonex, Rebif) • Glatiramer acetate (MHC interaction) • Combination therapy – for progressive dz • Combine with cyclophos or Mitoxantrone

  22. Question #5

  23. Migraine Headaches • Throbbing pain with photophobia and phonophobia. • Brainstem involvement results in nausea, pallor, flushing, tearing, rhinorrhea, and sinus congestion. • 60-70% with prodrome 24 hr prior • 15-25% with aura 1 hr prior

  24. Migraine Headaches • Treatment • NSAIDs – nonspecific; for mild headaches • Triptans – direct trigeminal nerve binding; for moderate to severe headaches • Contraindicated in CAD • Ergot derivatives – hospitalized patients • Rescue medications – Haldol, lidocaine, magnesium, dilantin, tizanidine, zyprexa. • Opioids can be used occasionally

  25. Distinguishing Headaches • Migraine/Cluster versus Tension • Cause disability versus able to work through them • Migraine versus Cluster • Stay still versus pace and even strike head • >4 hours versus <3 hours

  26. Question #6

  27. Question #7

  28. Epilepsy • Two or more unprovoked seizures • Etiologies: unknown (ideopathic) or focal abn (symptomatic) • Vascular malformation • Tumor • Restricted scar • Focal cortical dysgenesis

  29. Epilepsy Treatment • After first seizure – decision to start treatment is individualized • No driving for 6 months to 1 year • Risk for recurrence is 30 to 60%. • Abnormal EEG indicates higher risk • After second seizure recurrance rate is 80 to 90%.

  30. Epilepsy Treatment • Choice of medication • Absence – Ethosuximide • GTC – Phenytoin, Carbamazepine, Phenobarbital, Valproate • Partial – Gabapentin, Lamotrigine, topiramate, oxcarbazepine • Cognitive impairment – Phenobarb, Phenytoin, Carbamazepine, Topiramate

  31. Status Epilepticus • Secure ABCs – including intubation • Ativan 0.1 mg/kg then • Phenytoin/phos-phenytoin 18 mg/kg • Phenobarbitol 15 mg/kg • Pentobarbitol 5-15 mg/kg

  32. Question #8

  33. Question #8

  34. Primary CNS Lymphoma • Presentation: confusion, lethargy, memory loss, focal neuro signs, and/or seizures • Solitary or multiple brain masses • Diagnostic evaluation • Evaluation for uveitis, retinitis • CSF EBV viral load • brain biopsy • Treat with MTX and whole brain XRT

  35. Toxoplasmic Encephalitis • Similar presentation to PCNSL • Diagnostic criteria • Seropositive for Toxo IgG antibody • CD4 < 100 and not getting prophy • Multiple ring-enhancing lesions on MRI • If all three present 90% likelihood • Presumptive pyrimethamine/sulfadiazine • Otherwise brain biopsy recommended.

  36. Question #9

  37. Compressive myelopathy • Presentation: • Initial spinal or radicular pain • Bilateral motor or sensory dysfxn • No brain or brainstem findings • Evaluate with MRI spine • Surgical decompression for epidural abscess and spondylosis • Steroids and XRT vs. surgery for epidural tumors

  38. Question #10

  39. Question #10

  40. Question #10

  41. Question #10

  42. Viral Encephalitis • Symptoms of encephalitis • AMS – subtle to unresponsive • Usually no meningeal signs • Seizures common • Focal neurologic findings; abn reflexes • CT/MRI Findings • VZV, HSV, HHV-6 – temporal lobe • West Nile – temporal lobe, basal ganglia, thalamus, brainstem, cerebellum

  43. Viral Encephalitis • CSF Findings • Elevated protein but <150 mg/dl • Normal glucose • Elevated WBC count but <250/mm3 • No red cells except in HSV

  44. References • MKSAP 14 – Neurology • MKSAP 14 – Infectious Disease • Uptodate Online

More Related